J P Morgan Chase & Co reissued their neutral rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note published on Thursday.

Several other equities research analysts also recently weighed in on the company. Deutsche Bank AG set a GBX 1,610 ($21.71) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a report on Thursday. Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a research note on Wednesday. Berenberg Bank reiterated a buy rating and issued a GBX 1,835 ($24.74) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday. Bryan, Garnier & Co reiterated a neutral rating and issued a GBX 1,710 ($23.06) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday. Finally, Jefferies Group LLC cut their price objective on GlaxoSmithKline plc from GBX 1,750 ($23.59) to GBX 1,675 ($22.58) and set a buy rating for the company in a research report on Monday. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of GBX 1,698.52 ($22.90).

GlaxoSmithKline plc (GSK) traded up 0.41% during trading on Thursday, reaching GBX 1474.00. 5,726,851 shares of the company’s stock were exchanged. The stock has a 50-day moving average of GBX 1,503.38 and a 200-day moving average of GBX 1,606.97. The stock’s market capitalization is GBX 72.05 billion. GlaxoSmithKline plc has a 52 week low of GBX 1,444.00 and a 52 week high of GBX 1,745.56.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline plc (GSK) Given Neutral Rating at J P Morgan Chase & Co” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/22/glaxosmithkline-plc-gsk-given-neutral-rating-at-j-p-morgan-chase-co.html.

The firm also recently disclosed a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be given a dividend of GBX 19 ($0.26) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.23%.

In other GlaxoSmithKline plc news, insider Manvinder Singh Banga acquired 2,267 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was acquired at an average price of GBX 1,599 ($21.56) per share, with a total value of £36,249.33 ($48,873.30). Also, insider Patrick Vallance acquired 861 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.81) per share, with a total value of £13,930.98 ($18,782.50). Insiders have purchased a total of 3,152 shares of company stock valued at $5,055,023 in the last three months.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.